Related by context. All words. (Click for frequent words.) 72 proteasome inhibitors 72 MEK inhibitors 71 kinase inhibitor 71 molecularly targeted 71 HDAC inhibitors 71 anticancer agents 70 small molecule inhibitors 69 vascular disrupting agents 69 PARP inhibitors 68 selective inhibitors 68 histone deacetylase inhibitors 67 JAK inhibitors 67 chemotherapeutics 67 EGFR inhibitors 67 PI3K inhibitor 67 HDAC inhibitor 66 PI3K inhibitors 66 HDAC 66 VEGF inhibitors 66 tyrosine kinase inhibitor 66 Pertuzumab 66 protease inhibitors 66 multitargeted 66 tyrosine kinase inhibitors 65 GPCR targets 65 Hsp# inhibition 65 antisense oligonucleotides 65 anticancer therapies 65 protein kinase inhibitor 65 anticancer drugs 65 IAP inhibitors 65 JAK3 65 Hsp# inhibitors 65 mTOR inhibitors 65 proteasome inhibitor 65 histone deacetylase HDAC inhibitors 65 JAK2 inhibitors 65 HDACs 65 Zolinza 65 FLT3 64 delta isoform 64 SERMs 64 TLR9 agonists 64 EGFr 64 polymerase inhibitors 64 epothilone 64 PI3 kinase 64 PLX# 64 small molecule 64 Symadex 64 ErbB3 HER3 64 BCR ABL 64 mAbs 64 molecular biomarkers 64 small molecule inhibitor 64 HDACi 64 HCV protease inhibitors 64 cancer immunotherapies 64 chemotherapeutic agents 64 MAbs 64 Bortezomib 64 PXD# 64 peptide antigens 64 BCR ABL inhibitors 64 anti angiogenic agents 64 antisense 64 taxanes 64 FGFR 63 receptor tyrosine kinase inhibitor 63 VEGF receptor 63 small molecule tyrosine 63 renin inhibitors 63 Nanobodies 63 SARMs 63 HSP# inhibitor 63 novel peptide 63 cancer therapeutics 63 PARP inhibitor 63 kinases 63 histone deacetylase HDAC inhibitor 63 antisense drugs 63 receptor antagonists 63 kinase 63 VEGF Trap 63 monoclonal antibodies 63 OMP #M# 63 predictive biomarkers 63 JAK1 63 mAb 63 Epothilones 63 chemotherapeutic drugs 63 PI3K 63 siRNA therapeutics 63 immunotherapies 63 protein kinase inhibitors 63 CCR5 antagonists 63 Vorinostat 63 NS4A 63 IAP inhibitor 63 imatinib Gleevec 63 ENMD # 63 HDAC inhibition 63 cyclin dependent kinases 63 angiogenesis inhibitors 63 HGS# 62 A3 adenosine receptor 62 integrase inhibitors 62 fusion proteins 62 Squalamine 62 biologic therapeutics 62 PDGF receptor 62 pertuzumab 62 Sphingomab 62 Syk 62 JAK inhibitor 62 aptamers 62 IGF 1R 62 erlotinib Tarceva 62 CD# antibodies 62 Onconase 62 obatoclax 62 EGF receptor 62 Gefitinib 62 epothilones 62 antiviral compounds 62 AEG# 62 selective inhibitor 62 histone deacetylase 62 biomarkers 62 anti CD3 62 erlotinib Tarceva ® 62 Monoclonal antibodies 62 GPCRs 62 BAY #-# 62 Aurora kinase 62 gefitinib Iressa 62 ixabepilone 62 TRV# [001] 62 MEK inhibitor 62 Tumor Necrosis Factor 62 ErbB3 62 vascular disrupting agent 62 EGFR TKIs 62 Panzem 62 immunotherapeutic 62 Hsp# inhibitor 62 antisense compounds 62 preclinically 62 selective inhibition 61 TLR8 61 OXi# 61 Kinase 61 miR #a [002] 61 gamma secretase inhibitors 61 targeting CD# 61 Nanobody ® 61 enzastaurin 61 PI3K/mTOR 61 epigenetic therapies 61 therapeutic monoclonal antibodies 61 CB1 antagonists 61 Anticalin 61 CRTH2 61 humanized antibody 61 NNRTIs 61 nucleoside 61 metaglidasen 61 Aurora kinase inhibitor 61 anti angiogenic 61 c MET 61 EGFR 61 immunomodulatory 61 CCR5 antagonist 61 sodium glucose cotransporter 61 PDE4 inhibitor 61 histone methyltransferases HMTs 61 receptor agonists 61 AMPK activators 61 CCX# 61 biologic therapies 61 TLR agonists 61 tumor subtypes 61 Fleximer 61 myeloproliferative disorders 61 PTP 1B 61 XmAb# 61 Crizotinib 61 biomarker 61 antisense oligonucleotide 61 JAK2 61 Nexavar ® 61 therapeutics 61 JAK2 inhibitor 61 vorinostat 61 RGB # 61 Bafetinib 61 dasatinib Sprycel 61 deacetylase inhibitors 61 IMC A# 61 antitumor 61 Janus Kinase 61 investigational humanized monoclonal antibody 61 VEGFR2 61 T#I [002] 61 Vilazodone 61 insulin sensitizers 61 nucleoside analogues 61 Blinatumomab 61 disease modifying 61 CCR2 61 p# inhibitors 61 Protein Kinase C 61 rxRNA 61 Epidermal Growth Factor Receptor 61 inhibitors 61 ligands 61 TNF alpha inhibitors 61 resolvins 61 kinase inhibition 61 myelofibrosis polycythemia vera 61 orally bioavailable 61 PSN# [002] 61 anti angiogenic drugs 61 T DM1 61 ALK inhibitor 60 HuLuc# 60 hypoxia inducible factor 60 ganetespib 60 geldanamycin 60 GRN#L 60 Curaxin 60 P#X# 60 histone deacetylase HDAC 60 breast cancer subtypes 60 nucleosides 60 poly ADP ribose polymerase 60 G Protein Coupled 60 Seliciclib 60 Xanafide 60 anti CD# antibodies 60 anti VEGF 60 histone deacetylase inhibitor 60 p# inhibitor 60 protein kinases 60 OncoVEX 60 epigenetic therapeutics 60 AKT inhibitor 60 LY# [003] 60 tyrosine kinases 60 TLR9 agonist 60 histone deacetylases 60 Gleevec resistant 60 GPR# [002] 60 immune modulators 60 cyclin dependent kinase inhibitor 60 TKIs 60 EOquin 60 chemotherapeutic drug 60 AP# [003] 60 BMS # 60 antagomirs 60 prodrugs 60 xenograft models 60 selective kinase inhibitor 60 HER1 60 orally administered inhibitor 60 EGFR tyrosine kinase inhibitors 60 sapacitabine 60 Perifosine 60 splice variants 60 NEUGENE 60 AMN# [001] 60 MAb 60 immunomodulators 60 XmAb 60 bevacizumab Avastin 60 Debio 60 Locked Nucleic Acid LNA 60 topoisomerase 60 neratinib 60 radiation sensitizer 60 antisense drug 60 Aplidin 60 Kinase inhibitors 60 pan HDAC inhibitor 60 antibody fragment 60 protease inhibitor 60 anti angiogenesis 60 cytotoxic 60 receptor modulators 60 humanized anti 60 Nanobody 60 liposomal formulation 60 CYT# potent vascular disrupting 60 tyrosine kinase 60 allosteric modulators 60 humanized antibodies 60 Herceptin trastuzumab 60 telomerase inhibitor 60 PORxin TM 60 Factor VIIa 60 bispecific antibody 60 novel anticancer 60 tubulin inhibitor 60 potently inhibit 60 humanized monoclonal antibodies 60 peroxisome proliferator activated 60 ErbB 60 druggable targets 60 Bevacizumab 60 Inhibitors 60 UsiRNAs 60 PI3K delta 60 CD# antibody [001] 60 Kinase Inhibitor 60 anticancer therapeutics 60 cellular pathways 60 fusion inhibitors 60 oral prodrug 60 TLR Therapeutics 60 DOS# 60 preclinical compounds 60 exon skipping 60 therapies 60 BRAF inhibitor 60 IGF IR 60 mitotic kinesins 60 angiogenesis inhibitor 60 Novartis Gleevec 60 nucleoside analogs 60 Carfilzomib 60 siRNA mediated 60 HER3 60 tafamidis 59 HCV protease 59 Tyrima 59 cilengitide 59 NS5A 59 antibody 59 antitumoral 59 VDAs 59 oncology therapeutics 59 chemokine receptor 59 nucleoside analogue 59 siRNA therapeutic 59 novel kinase inhibitors 59 inhibitor 59 Tarvacin 59 IMA# 59 Fibroblast Growth Factor Receptor 59 tumor antigen 59 oncolytic 59 oxidative stress inducer 59 Erlotinib 59 bioinformatic approaches 59 immune modulating 59 RNAi therapeutic targeting 59 pomalidomide 59 G CSF 59 biomarker identification 59 chemotherapeutic agent 59 orphan GPCRs 59 humanized monoclonal antibody 59 GAP #B# 59 chemokine 59 Kinases 59 adenosine receptor 59 molecularly targeted therapies 59 CETP inhibitors 59 anticancer agent 59 ALK inhibitors 59 TNF inhibitors 59 endothelin receptor antagonists 59 prognostic markers 59 MGCD# [001] 59 selectively inhibit 59 CobaCyte 59 CDK inhibitors 59 microRNAs 59 BiTE 59 immunotherapeutics 59 TNFa 59 effector function 59 anti TNF 59 paclitaxel Taxol 59 Talabostat 59 VEGF receptors 59 isoform selective 59 Smac mimetic 59 chemoresistance 59 dAbs 59 siRNA 59 humanised monoclonal antibody 59 highly selective inhibitor 59 PEP# [003] 59 Dasatinib 59 PKC# 59 HDAC Inhibitor 59 HIV integrase inhibitor 59 serine protease 59 allosteric 59 Voreloxin 59 HGS ETR1 59 antibody therapeutics 59 Fc fusion protein 59 mTOR inhibitor 59 imatinib Gleevec ® 59 Guanilib 59 elvitegravir 59 bortezomib 59 anti angiogenic agent 59 Chemokine Receptor 59 Janus kinase 59 GPR# agonists 59 JAK#/JAK# 59 PARP inhibition 59 enzyme inhibitors 59 Imatinib 59 targeted radiotherapeutic 59 polymerase inhibitor 59 nanoviricides 59 novel immunomodulatory 59 oncolytic viruses 59 EGFR antibodies 59 phage display 59 trastuzumab Herceptin 59 CTLA 4 59 Aptamer 59 NKT cells 59 clinically validated targets 59 Monoclonal Antibody 59 SGLT inhibitors 59 TLR9 59 proprietary LNA 59 Targretin 59 pharmacogenetic 59 Celator 59 LRRK2 59 flavopiridol 59 Stapled Peptide 59 Clusterin 59 GPCR 59 allosteric modulator 59 SIRT1 activators 59 cancer immunotherapy 59 Maraviroc 59 Sym# 59 thrombin receptor 59 HER2 receptor 59 anticancer compounds 59 taxane 59 selective antagonists 59 shRNA libraries 59 protein kinase C 59 MyVax R 59 adenoviral 59 anticancer therapy 59 selective androgen receptor modulators 58 Antisense 58 WT1 58 antimitotic 58 nicotinic alpha 7 58 PNP inhibitor 58 estrogen receptor beta 58 Aurora Kinase 58 chemotherapeutic 58 Hedgehog signaling pathway 58 Factor Receptor 58 Fulvestrant 58 pro angiogenic 58 Pathway Inhibitor 58 potent anticancer 58 Vidofludimus 58 immunotoxin 58 Nanobodies ® 58 fluoropyrimidine 58 EGFR HER 58 vinca alkaloid 58 interferons 58 sigma receptors 58 small molecule defensin 58 mutational status 58 oral antiviral 58 investigational therapies 58 chimeric monoclonal antibody 58 antiangiogenic 58 androgen receptor 58 cortisol receptor 58 NFkB 58 CA4P 58 BRAF mutation 58 cMET 58 Tarvacin TM 58 Archexin 58 integrase inhibitor 58 peptidomimetic 58 PRT# 58 lapatinib Tykerb 58 thrombopoietin 58 CXCR4 58 YONDELIS 58 preclinical 58 Smac mimetics 58 aptamer therapeutics 58 microtubule targeting 58 TLR8 agonist 58 potent inhibitor 58 aminoglycosides 58 Avastin bevacizumab 58 PIK3CA 58 cediranib 58 Liposomal 58 tigecycline 58 immune stimulatory 58 Panzem R NCD 58 endostatin 58 cytostatic 58 DFMO 58 neuraminidase inhibitors 58 PDE4 inhibitors 58 FGFR1 58 monoclonal antibody 58 S1P 58 CDKs 58 multi kinase inhibitor 58 Mitoxantrone 58 SGLT2 inhibitors 58 biomarker discovery 58 Ceflatonin 58 small molecule modulators 58 vemurafenib 58 nicotinic acetylcholine receptor 58 metabotropic glutamate receptor 58 Rituximab 58 CCR5 inhibitor 58 non nucleoside HCV 58 immunomodulator 58 THR beta agonist 58 DXL# 58 STAT3 58 CYC# 58 therapeutic antibody 58 Antibody 58 protein therapeutics 58 immunosuppressive 58 tranilast 58 eIF 4E 58 reversible inhibitor 58 beta interferons 58 HIV protease inhibitors 58 Maribavir 58 cytotoxic agents 58 LEX System 58 antithrombotic 58 cetuximab Erbitux R 58 multikinase inhibitor 58 celgosivir 58 telomerase inhibitors 58 Raltegravir 58 PEG SN# 58 antiviral therapies 58 antimetastatic 58 ZFPs 58 novel VDA molecule 58 CBLC# 58 HIV protease 58 tumor antigens 58 Olaparib 58 antiangiogenic agents 58 liposomal 58 DNA methyltransferases 58 elotuzumab 58 cell signaling pathways 58 iSONEP 58 Tesmilifene 58 Azedra 58 Apaziquone 58 HepDirect 58 small molecule agonists 58 interferon IFN 58 GPR# [001] 58 p# mitogen activated 58 immunological diseases 58 anti fibrotic 58 Sorafenib 58 Pazopanib 58 mda 7 58 dacetuzumab 58 serotonin receptor 58 secreted proteins 58 PKM2 58 aptamer 58 HIV integrase inhibitors 58 bevacizumab Avastin ® 58 EZN 58 PLK1 58 trabectedin 58 clusterin 58 MLN# 58 echinocandins 58 Inhibitor 58 alvespimycin 58 LSD1 58 OvaRex R 58 mGluR2 NAM 58 ENMD 58 eniluracil 58 Intravenous CP 58 Phylomer ® 58 direct thrombin inhibitors 58 idarubicin 58 Regado 58 XL# XL# 58 FTIs 58 MetMAb 58 MET amplification 58 diagnostic biomarkers 58 therapeutic monoclonal antibody 57 rNAPc2 57 HDAC6 57 nucleotide analogs 57 camptothecin 57 EGFR mutation 57 tumor vasculature 57 nutlin 57 M2 subunit 57 signal transduction inhibitor 57 mapatumumab 57 Aurora kinases 57 VitiGam 57 PI3K/Akt pathway inhibitor 57 epithelial tumors 57 drug conjugate 57 PDE# 57 Hedgehog pathway 57 partial agonist 57 potent inhibitors 57 tiapamil 57 SGLT 2 57 EndoTAGTM 1 57 induce apoptosis 57 genetic biomarkers 57 IMiDs 57 TRAIL receptor 57 galectin 3 57 uric acid lowering 57 dasatinib 57 sorafenib Nexavar 57 NNR Therapeutics 57 vinca alkaloids 57 anti mitotic 57 agonist compounds 57 EpCAM 57 S#P# 57 fusion inhibitor 57 MMP inhibitors 57 chemotherapies 57 talabostat 57 5 HT2A inverse 57 Epratuzumab 57 miR #b [002] 57 Omacetaxine 57 fusion protein 57 anticancer treatments 57 hedgehog pathway 57 marketed EGFR 57 NXL# 57 atacicept 57 visilizumab 57 epigenetic enzymes 57 cyclophilin inhibitor 57 Preclinical studies suggest 57 mimetics 57 otelixizumab 57 Trophos 57 OMAPRO 57 potent antiproliferative 57 dipeptidyl peptidase 4 57 synthetic retinoid 57 DsiRNA 57 INT# [002] 57 cyclin dependent kinases CDKs 57 Dapagliflozin 57 EGFR pathway 57 Clofarabine 57 carfilzomib 57 2 inhibitor CYT# 57 Litx 57 Survivin 57 daclizumab 57 PI3K Akt 57 demethylating agents 57 inhibit EGFR 57 splice variant 57 Sapacitabine 57 calcineurin inhibitors 57 Pimavanserin 57 CXCR4 receptor 57 Aurora kinase inhibitors 57 molecularly targeted therapy 57 miRNA 57 TG# [003] 57 NexACT 57 tanespimycin 57 glucagon receptor 57 RAF kinase 57 selective androgen receptor modulator 57 Angiolix 57 MEK ERK 57 Dalbavancin 57 muscarinic 57 CCR5 inhibitors 57 HGS ETR2 57 protein tyrosine phosphatases 57 ubiquitin ligases 57 reverse transcriptase inhibitors 57 investigational compounds 57 brostallicin 57 peripherally acting 57 KinomeScan 57 bendamustine 57 proteases 57 prostone 57 miRNAs 57 CDK4 57 EGFR mutations 57 Like Receptor 57 PPAR gamma 57 MDM2 57 AT1R 57 MGd 57 Treanda 57 azoles 57 Temsirolimus 57 dexpramipexole 57 ETBs 57 VEGFR 57 AZD# 57 Vandetanib 57 oncoproteins 57 radionuclide therapy 57 Cylene 57 anticancer 57 docetaxel Taxotere 57 Romidepsin 57 oxazolidinone 57 SIMPLE Antibody TM 57 CENP E 57 CDDO Im 57 microtubule inhibitor 57 topotecan 57 Targeted Chemotherapy 57 signal transduction inhibitors 57 ERBB2 57 NTDDS 57 Affibody ® molecules 57 Flt3 57 indibulin 57 CEQ# 57 HCV polymerase inhibitor 57 stable nucleic acid 57 PGE2 57 antisense inhibitors 57 RONDEL 57 pan Bcl 2 57 vimentin 57 nucleoside analog 57 Receptors GPCRs 57 amrubicin 57 cyclin D1 57 micro RNAs 57 MDV# 57 peptide 57 tumor suppressor genes 57 cyclin dependent kinase CDK 57 peptibody 57 echinocandin 57 Wnt signaling pathway 57 panobinostat 57 alpha folate receptor 57 CORT # 57 KSP inhibitors 57 Camptothecin 57 PI3 Kinase 57 Small Molecule 57 sorafenib 57 sphingosine kinase 57 erlotinib 57 PKCi 57 biased ligands 57 seliciclib 57 LNP formulations 57 TNFα 57 Velcade bortezomib 57 oral Factor Xa 57 ADAM# 57 chemokine receptors 57 Interferon alpha 57 CD# [002] 57 cytotoxics 57 OHR/AVR# 57 beta lactams 57 agonists 57 milatuzumab 57 RNA antagonists 57 Taxanes 57 EGFRvIII 57 PI3 K 57 #HT#A 57 Vidaza azacitidine 57 depsipeptide 57 decitabine 57 targeted biologic therapies 57 #D#C# 57 tumor suppressors 57 galectin 57 Panzem NCD 57 GV# [001] 57 Anti angiogenic 57 melanocortin receptor agonists 57 microRNA miR 57 vanilloid receptor 57 immunomodulatory therapy 57 tyrosine kinase inhibitors TKIs 57 deacetylase 57 TRC# 57 DNA gyrase 57 aurora kinase 57 interferon lambda 57 peptides 57 uPAR 57 thalidomide Thalomid 57 PPARγ 57 nanocarriers 57 PEGylated 57 ansamycin 57 glioma cells 57 HCV protease inhibitor 57 PEGylated interferon 57 intracellular signaling pathways 56 siRNA compounds 56 gefitinib 56 raltegravir 56 CD# monoclonal antibody 56 TELINTRA 56 bortezomib Velcade 56 Bcl 2 56 KLF4 56 synthetic peptides 56 RNA antagonist 56 Aliskiren 56 XYOTAX TM 56 oncogenic 56 phosphatases 56 vidofludimus 56 cytoprotective 56 Src inhibitors 56 diagnostic biomarker 56 selective HDAC inhibitors 56 short interfering RNA 56 tumor microenvironment 56 NRTIs 56 Protease inhibitors 56 Li Fraumeni 56 ErbB2 56 integrin receptors 56 microRNA 56 pharmacogenetics 56 pro apoptotic 56 selectively inhibited 56 anti angiogenic therapies 56 natriuretic peptide 56 pharmacological chaperone 56 PKC isoforms 56 Eg5 56 EndoTAG 56 DGAT1 inhibitors 56 CYT# novel 56 MAPK pathway 56 enzyme inhibitor 56 Anticalins 56 pharmacodynamic biomarkers 56 Anticalins R 56 Anticalin R 56 Pralatrexate 56 EphA2 56 orally dosed 56 oral proteasome inhibitor 56 signaling cascades 56 Tasimelteon 56 CYT# 56 ALS #-# 56 Gemcitabine 56 soluble receptor 56 estrogen receptor 56 hematological cancers 56 pharmacologic agents 56 insulin sensitizer 56 ADP receptor antagonist 56 oncogenes 56 retinoic acid receptor 56 gastrointestinal stromal tumors 56 personalized immunotherapy 56 FGFR3 56 Trastuzumab 56 GSK3B 56 Enzastaurin 56 chemopreventive agent 56 Docetaxel 56 XmAb ™ 56 favorable pharmacokinetic profile 56 ALK mutations 56 antisense inhibitor 56 hERG 56 molecular pathways 56 apoptosis inducing 56 RNAi therapeutic 56 liposomal doxorubicin 56 Daclizumab 56 siRNAs 56 anti leukemic 56 OGeS 56 oncology indications 56 HIV protease inhibitor 56 Adnectins 56 thiazolides 56 Biomerk Tumorgrafts 56 Amrubicin 56 Cytochrome P# 56 antineoplastic 56 cytochrome P# 56 MKC# MKC# PP 56 chemical entities NCEs 56 gemcitabine Gemzar 56 Mipomersen 56 methyltransferases 56 MAPK 56 survivin 56 Abl 56 polyketides 56 Tesetaxel 56 imatinib mesylate 56 MDSCs 56 selective immunoproteasome inhibitor 56 phosphate S1P 56 insulin sensitizing 56 nanomolar 56 CTLA4 Ig 56 LY# [002] 56 trastuzumab Herceptin R 56 ALN TTR 56 ASONEP 56 GPR# agonist 56 YONDELIS R 56 tyrosine kinase receptor 56 olaparib 56 5alpha reductase 56 TriRima 56 cell malignancies 56 Elvitegravir 56 Bcr Abl 56 Aflibercept 56 Eribulin 56 Src 56 CDK inhibitor 56 NuMimetic TM 56 humanised antibody 56 DNA intercalator 56 BiPar 56 Plexxikon 56 PROfusion 56 Nexavar sorafenib 56 photosensitizer 56 AVI NEUGENE 56 miRview mets 56 monoclonal 56 VEGF pathway 56 hematologic malignancies 56 dipeptidyl peptidase IV 56 monoclonal antibody therapies 56 HQK 56 CCR9 antagonist 56 companion diagnostics 56 IFN alpha 56 Atiprimod 56 protein mTOR 56 INCB# [001] 56 MUC1 56 Akt activation 56 stem cell therapeutics 56 antifolates 56 Sutent sunitinib 56 antiviral therapeutics 56 monoclonal antibody therapeutics 56 virulence genes 56 Trastuzumab DM1 56 Interferon alfa 56 ATL# [001] 56 Ixabepilone